Apixaban Chemical Structure (Apixaban Struct)
Eliquis Tablet, Film Coated
Product Images NDC 55154-0612
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Eliquis (NDC 55154-0612). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
D9f4bccb Df6a 43d3 Ad27 F9d0682f054c 00
D9f4bccb Df6a 43d3 Ad27 F9d0682f054c 01
D9f4bccb Df6a 43d3 Ad27 F9d0682f054c 02
ELIQUIS (apixaban) tablets, 2.5mg strength, are available in a bottle of 4140 tablets. The tablets should be kept out of reach of children. No further information is available as the given text contains errors.*
D9f4bccb Df6a 43d3 Ad27 F9d0682f054c 03
This is a description of Eliquis Tablets with 2.5 mg of Apixaban in each of the 10 tablets contained within the package. It advises that the full dosage information, prescribing information, precautions and warnings can be found in the product insert. It has specific storage recommendations between 20°C and 25°C with allowances for excursions between 15°C and 30°C. The package also contains a warning that it is not child resistant and intended for institutional use only. It is recommended to be kept out of reach of children in child-resistant containers if dispensed for outpatient use. The package should not be used if any printed blister units are opened or torn. The product is marketed in the United States by Bristol-Myers Squibb Company in New Jersey and Pfizer Inc in New York. The product is distributed by Cardinal Health in Dublin, Ohio.*
Aristotle Forest Plot (Eliquis Clin Forest Fig5)
Aristotle Major Bleeding Forest Plot (Eliquis Forest Fig1)
This is a table of results obtained from a study comparing the efficacy of Apixaban and Warfarin as treatments for preventing strokes in patients with Atrial Fibrillation. The table indicates the number of events, patients per year, and the Hazard Ratio for each subgroup of patients. The subgroups are classified according to several factors such as age, gender, weight, diabetes mellitus, and other parameters. The results show that Apixaban performed better than Warfarin in most cases.*
Aristotle Kaplan-meier Curve (Eliquis Km Fig4)
Effect Of Coadministered Drugs On Pharmacokinetics Of Apixaban (Eliquis Pkplot Drugs Fig2)
This appears to be a table showing the effect of various drug interactions on the PK Fold Change and 90% confidence interval, specifically looking at combined P-gp and strong CYP3A4 inhibitors, other CYP3A4 and P-gp inhibitors, and combined P-gp and strong CYP3A4 inducers. The table lists the drug names and dosages and indicates the observed changes in AUC relative to a reference measurement. There are also some numerical values listed that appear to be indicating the degree of change observed in the study.*
O:\e-submissions\pbo\products\eliquis 202155\08. Pas Esrd Dosing\01. Orig Submission\source\eliquis-pkplot-pop-fig3.jpg (Eliquis Pkplot Pop Fig3)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
